Investor Relations

Diagonal Bio is a Swedish biotech company that has developed a ground breaking universal technology platform for the quick and accurate detection of genetic markers in genetic material (DNA and RNA).

Background

Diagonal Bio AB is a Swedish medical technology company founded in 2020 with the vision of limiting the spread of infectious diseases by creating a user-friendly, cost-effective diagnostic platform with high accuracy. Based on its patented technology, Diagonal Bio plans to develops a diagnostic systems, PANVIRAL™, that have the potential to fulfill the vision and thereby facilitate the challenge of rapidly and accurately identifying genetic markers for infectious diseases.

Diagonal Bio’s patented technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®).

Diagonal Bio’s patented technology

Diagonal Bio’s patented technology offers the same accuracy as today’s leading diagnostic method, PCR, but is not dependent on complicated logistics or large central laboratories and is therefore significantly faster and more cost-effective. With the help of the Company’s technology, today’s and future infectious diseases can be diagnosed within 10–15 minutes of sampling, in connection with a visit to, for example, a primary care unit.

Diagonal Bio’s platform technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®). This, too, with the same high accuracy as today’s PCR-based techniques, but in a significantly faster, simpler and more cost-effective.

Press Releases

Diagonal Bio AB publish – White paper

Non-regulatory

Diagonal Bio’s platforms using an 8-parallel test format, show overall Accuracy of 99.6 %, Sensitivity of 100 %, and Specificity of 99.5 %.

Read more

Diagonal Bio AB strengthens its go-to-market strategy through an agreement with founding partner Johan Källstrand

Non-regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or the “Company”) today announces a strategic step to strengthen its sales and marketing efforts. The company has secured the commitment of Johan Källstrand, one of the company’s founders with extensive experience and knowledge within the company’s market areas. The agreement means that Diagonal Bio is supported by Källstrand’s long experience and deep knowledge to strengthen its go-to-market strategy.

Read more

The subscription period in Diagonal Bio AB rights issue commences today

Non-regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Today, the 8[th] of April 2024, the subscription period in Diagonal Bio AB’s (“Diagonal Bio” or “the Company”) issue of units consisting of shares and consideration free warrants of series TO 1 (”TO 1”), with preferential right for the Company’s existing shareholders begins. The subscription period runs until the 22[nd] of April 2024. The issue volume initially amounts to a maximum of approximately SEK 32 million before transaction costs (the “Rights Issue”). Upon full subscription of the Rights Issue and full utilization of issued TO 1 at the highest subscription price, the Company may receive an additional approximately SEK 9.5 million before transaction costs. The Rights Issue is secured in writing by members of the board, management, existing shareholders, and external investors to a total of approximately 56.4 percent (corresponding to approximately SEK 18 million) through pre-subscription and guarantee commitments. A prospectus is available via the Company’s (www.diagonalbio.com), Sedermera Corporate Finance AB’s (www.sedermera.se) and Nordic Issuing AB’s (www.nordic-issuing.se) websites. The Company’s will today, the 8[th] of April 2024, present at an event with Financial Stockholm at Scandic Klara Hotell.

Read more

Diagonal Bio AB (publ) genomför en effektivisering av marknadskommunikation och ändrar från svenska till engelska för pressreleaser och delårsrapporter.

Non-regulatory

Diagonal Bio (“Bolaget”) meddelar att Bolaget valt att effektivisera sin marknadskommunikation och framöver endast kommer att tillhandahålla pressmeddelanden och delårsrapporter på engelska. Diagonal Bios årsredovisningar kommer även fortsättningsvis publiceras på svenska.

Read more

Valberedning utsedd i Diagonal Bio AB (publ.) inför årsstämman 2024

Non-regulatory

I enlighet med de principer för inrättande av valberedning som tidigare beslutats på årsstämman 2023, har följande valberedning utsetts för Diagonal Bio AB (publ.) inför årsstämman 2024.

Read more

Revisor

Mazars, Revision

Scheelevägen 17
223 63 Lund
Sweden

Contact us

Karin Wehlin
CEO, Diagonal Bio
Medicon Village, Lund
Phone: +46 (0)70 305 24 88
kw@diagonalbio.com

Certified advisor

Svensk Kapitalmarknadsgranskning AB
www.skmg.se

Phone: +46 (0)8 913 008
E-mail: ca@skmg.se

Issuer

Nordic Issuing AB
Stortorget 3
211 22 Malmö